The mouse core has been established to assist PPG member laboratories in the design, production and characterization of transgenic and knockout mouse strains. The mouse core will be responsible for all aspects of mouse engineering and will provide scientific advice on issues relating to mouse genetics and biology and to cancer modeling. Details on the construction of other mouse lines can be found in each of the accompanying proposals. We present the engineering of such mutant mouse strains as illustrative examples. These strains are the conditional PTEN knockout and the probascin-driven transgenic line. Specifically, for the production of transgenic mice, the facility will (i) maintain the core colony needed for production of the embryos and foster females, (ii) purify transgene inserts for microinjection, (iii) perform pronuclear microinjections, and (iv) conduct oviduct transfers, monitor births, and confirm transgenic founders. For the gene targeting experiments, the core responsibilities will be to (i) assist investigators in the design and construction of targeting vectors, (ii) conduct the ES transfections, selections, and clone picking and freezing, (iii) perform blastocyst microinjections of mutant ES cells, and (iv) perform uterine transfers and monitor chimera formation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA089021-01
Application #
6465948
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-05-01
Project End
2006-03-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Patnaik, Akash; Swanson, Kenneth D; Csizmadia, Eva et al. (2017) Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov 7:750-765
Lee, So Jin; Kim, Min Ju; Kwon, Ick Chan et al. (2016) Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev 104:2-15
Martin, Neil E; Gerke, Travis; Sinnott, Jennifer A et al. (2015) Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res 13:1431-40
Selvarajah, Shamini; Pyne, Saumyadipta; Chen, Eleanor et al. (2014) High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res 20:1521-30
González-Billalabeitia, Enrique; Seitzer, Nina; Song, Su Jung et al. (2014) Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov 4:896-904
Flavin, Richard; Pettersson, Andreas; Hendrickson, Whitney K et al. (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20:4904-11
Ittmann, Michael; Huang, Jiaoti; Radaelli, Enrico et al. (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718-36
Chen, Sen; Jiang, Xinnong; Gewinner, Christina A et al. (2013) Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal 6:ra40
Jia, Shidong; Gao, Xueliang; Lee, Sang Hyun et al. (2013) Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 3:44-51
Polkinghorn, William R; Parker, Joel S; Lee, Man X et al. (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3:1245-53

Showing the most recent 10 out of 94 publications